Byoung-Ju Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Byoung-Ju Kim has a total of 313 co-authors. Here are the top co-authors by number of shared publications:
- Soo-Jong Hong
Department of Pediatrics, Humidifier Disinfectant Health Center, National Medical Center, Seoul, Republic of Korea
40 shared publications Ju-Hee Seo
Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea
36 shared publications- Jinho Yu
Department of Pediatrics, Childhood Asthma Atopy Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
30 shared publications Hyo-Bin Kim
Department of Pediatrics, Inje University Sanggye Paik Hospital, Seoul, Korea
26 shared publicationsEun Lee
Department of Pediatrics, Inje University Haeundae Paik Hospital, Busan, Korea
22 shared publicationsHyung Young Kim
Department of Pediatrics, Pusan National University Yangsan Hospital, Pusan National University College of Medicine, Yangsan, Korea
22 shared publications
Latest Publications
- 1 July 2016
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 117 (1) , 91-92.e1
Clostridia in the gut and onset of atopic dermatitis via eosinophilic inflammation
- 1 July 2016
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 117 (1) , 91-92.e1
Clostridia in the gut and onset of atopic dermatitis via eosinophilic inflammation
Atopic dermatitis phenotype with early onset and high serum IL-13 is linked to the new development of bronchial hyperresponsiveness in school children
Background Atopic dermatitis (AD) is characterized by a heterogeneous clinical spectrum, and some forms of AD are associated with the initial steps of allergic march. The aims of this study were to determine AD phenotypes in school‐age children and investigate their associations with the allergic march in each cluster. Methods We included 242 children (6–8 years) with current AD from the Children's HEalth and Environmental Research study, a 4‐year prospective follow‐up study with 2‐year survey intervals. Latent class analysis was used. Serum IL‐13 and thymic stromal lymphopoietin (TSLP) levels at the time of enrollment were measured using ELISA. Results We identified four current AD phenotypes in children, characterized as ‘early onset with low atopy’ (26.4% of the sample; group 1), ‘early onset with high atopy and high eosinophil percentages’ (48.3%; group 2), ‘late onset with low atopy’ (9.9%; group 3), and ‘late onset with high atopy and normal eosinophils’ (15.3%; group 4). Although groups 2 and 4 demonstrated high atopic burden, children in group 2 showed the persistence of AD and eosinophilia associated with a high prevalence of new cases of bronchial hyper‐responsiveness and asthma symptoms during follow‐up. The serum IL‐13 level was significantly increased in the early‐onset AD groups, but there was no significant difference in the serum TSLP levels across all four groups. Conclusion An allergic march‐associated AD phenotype exists that is characterized by early onset of AD with its persistence, increased serum IL‐13 levels, high atopy, and a persistently increased blood eosinophil percentage.
Atopic dermatitis phenotype with early onset and high serum IL-13 is linked to the new development of bronchial hyperresponsiveness in school children
Background Atopic dermatitis (AD) is characterized by a heterogeneous clinical spectrum, and some forms of AD are associated with the initial steps of allergic march. The aims of this study were to determine AD phenotypes in school‐age children and investigate their associations with the allergic march in each cluster. Methods We included 242 children (6–8 years) with current AD from the Children's HEalth and Environmental Research study, a 4‐year prospective follow‐up study with 2‐year survey intervals. Latent class analysis was used. Serum IL‐13 and thymic stromal lymphopoietin (TSLP) levels at the time of enrollment were measured using ELISA. Results We identified four current AD phenotypes in children, characterized as ‘early onset with low atopy’ (26.4% of the sample; group 1), ‘early onset with high atopy and high eosinophil percentages’ (48.3%; group 2), ‘late onset with low atopy’ (9.9%; group 3), and ‘late onset with high atopy and normal eosinophils’ (15.3%; group 4). Although groups 2 and 4 demonstrated high atopic burden, children in group 2 showed the persistence of AD and eosinophilia associated with a high prevalence of new cases of bronchial hyper‐responsiveness and asthma symptoms during follow‐up. The serum IL‐13 level was significantly increased in the early‐onset AD groups, but there was no significant difference in the serum TSLP levels across all four groups. Conclusion An allergic march‐associated AD phenotype exists that is characterized by early onset of AD with its persistence, increased serum IL‐13 levels, high atopy, and a persistently increased blood eosinophil percentage.
- Open Access
- 1 January 2016
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 8 (5) , 471-477
Dynamics of Gut Microbiota According to the Delivery Mode in Healthy Korean Infants
Lee E, et al. Allergy Asthma Immunol Res. 2016 Sep;8(5):471-477. https://doi.org/10.4168/aair.2016.8.5.471
- 1 January 2016
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 8 (5) , 471-477
Open AccessDynamics of Gut Microbiota According to the Delivery Mode in Healthy Korean Infants
Lee E, et al. Allergy Asthma Immunol Res. 2016 Sep;8(5):471-477. https://doi.org/10.4168/aair.2016.8.5.471
- 1 December 2015
- Published by Elsevier in Materials Letters
- Vol. 161, 321-324
Characterization of graphene nanoplatelets prepared from polyimide-derived graphite
- 1 December 2015
- Published by Elsevier in Materials Letters
- Vol. 161, 321-324
Characterization of graphene nanoplatelets prepared from polyimide-derived graphite
- 20 August 2015
- Published by SPIE-Intl Soc Optical Eng
- p. 95490P-95490P-10
Cause of absorption band shift of disperse red-13 attached on silica spheres
- 20 August 2015
- Published by SPIE-Intl Soc Optical Eng
- p. 95490P-95490P-10
Cause of absorption band shift of disperse red-13 attached on silica spheres
- 18 August 2015
- Published by Taylor & Francis in Journal of Asthma
- Vol. 52 (10) , 1054-1059
Exhaled nitric oxide as a better diagnostic indicator for evaluating wheeze and airway hyperresponsiveness in preschool children
Objective: Fractional concentration of exhaled nitric oxide (FeNO) is a known marker of airway inflammation. The aims of this study were to evaluate FeNO, impulse oscillometry (IOS), and spirometry in preschool children and to investigate their relationship with wheeze and airway hyperresponsiveness (AHR). Methods: We performed a population-based, cross-sectional study with 561 children aged 5–6 years. A total of 544 children completed a modified International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire and eligible for the study. We measured FeNO, spirometry, methacholine bronchial provocation, and IOS. AHR was defined as the induction of a 20% decrease in FEV1(PC20) by a methacholine concentration ≤8.0 mg/dL. Results: Children who had wheeze or AHR had higher FeNO levels than children without these symptoms. However, neither IOS nor spirometry parameters showed significant differences between children with wheeze or AHR and those without. FeNO was associated with AHR, whereas IOS or spirometry parameters showed no association. Mean FeNO levels were positively correlated with a dose–response slope for methacholine, but neither IOS nor spirometry parameters showed significant correlations. Conclusions: FeNO is a more sensitive measurement of AHR and wheeze than spirometry or IOS in preschool children.
- 18 August 2015
- Published by Taylor & Francis in Journal of Asthma
- Vol. 52 (10) , 1054-1059
Exhaled nitric oxide as a better diagnostic indicator for evaluating wheeze and airway hyperresponsiveness in preschool children
Objective: Fractional concentration of exhaled nitric oxide (FeNO) is a known marker of airway inflammation. The aims of this study were to evaluate FeNO, impulse oscillometry (IOS), and spirometry in preschool children and to investigate their relationship with wheeze and airway hyperresponsiveness (AHR). Methods: We performed a population-based, cross-sectional study with 561 children aged 5–6 years. A total of 544 children completed a modified International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire and eligible for the study. We measured FeNO, spirometry, methacholine bronchial provocation, and IOS. AHR was defined as the induction of a 20% decrease in FEV1(PC20) by a methacholine concentration ≤8.0 mg/dL. Results: Children who had wheeze or AHR had higher FeNO levels than children without these symptoms. However, neither IOS nor spirometry parameters showed significant differences between children with wheeze or AHR and those without. FeNO was associated with AHR, whereas IOS or spirometry parameters showed no association. Mean FeNO levels were positively correlated with a dose–response slope for methacholine, but neither IOS nor spirometry parameters showed significant correlations. Conclusions: FeNO is a more sensitive measurement of AHR and wheeze than spirometry or IOS in preschool children.
- 1 March 2015
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 135 (3) , 827-830.e5
Claudin-1 polymorphism modifies the effect of mold exposure on the development of atopic dermatitis and production of IgE
- 1 March 2015
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 135 (3) , 827-830.e5
Claudin-1 polymorphism modifies the effect of mold exposure on the development of atopic dermatitis and production of IgE
- Open Access
- 1 January 2015
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 7 (6) , 573-582
Prenatal Particulate Matter/Tobacco Smoke Increases Infants' Respiratory Infections: COCOA Study
Yang SI, et al. Allergy Asthma Immunol Res. 2015 Nov;7(6):573-582. https://doi.org/10.4168/aair.2015.7.6.573
- 1 January 2015
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 7 (6) , 573-582
Open AccessPrenatal Particulate Matter/Tobacco Smoke Increases Infants' Respiratory Infections: COCOA Study
Yang SI, et al. Allergy Asthma Immunol Res. 2015 Nov;7(6):573-582. https://doi.org/10.4168/aair.2015.7.6.573
- Open Access
- 1 January 2015
- Published by The Korean Academy of Asthma, Allergy and Clinical Immunology and The Korean Academy of Pediatric Al in Allergy, Asthma & Immunology Research
- Vol. 7 (2) , 167-174
Association Between Antibiotic Exposure, Bronchiolitis, and TLR4 (rs1927911) Polymorphisms in Childhood Asthma
Lee E, et al. Allergy Asthma Immunol Res. 2015 Mar;7(2):167-174. https://doi.org/10.4168/aair.2015.7.2.167
- 1 January 2015
- Published by The Korean Academy of Asthma, Allergy and Clinical Immunology and The Korean Academy of Pediatric Al in Allergy, Asthma & Immunology Research
- Vol. 7 (2) , 167-174
Open AccessAssociation Between Antibiotic Exposure, Bronchiolitis, and TLR4 (rs1927911) Polymorphisms in Childhood Asthma
Lee E, et al. Allergy Asthma Immunol Res. 2015 Mar;7(2):167-174. https://doi.org/10.4168/aair.2015.7.2.167
- 1 January 2015
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 135 (1) , e216-e220
Intrapulmonary Recombinant Factor VIIa for Diffuse Alveolar Hemorrhage in Children
Diffuse alveolar hemorrhage (DAH) is a life-threatening pulmonary complication in patients with hematologic malignancies or autoimmune disorders, and it has a high mortality rate. The current treatment options of corticosteroids, transfusions, and immunosuppressants have been limited and largely unsuccessful, and they can be accompanied by multiple complications. Intrapulmonary administration of recombinant activated factor VII (rFVIIa) has been reported in adults, but there are scarce data on its use in children. The present article reviews our institutional experience with intrapulmonary rFVIIa for the treatment of DAH in children. The study included 6 pediatric patients with acute, bronchoscopically confirmed DAH treated between 2011 and 2013. The median age was 11 years, and patient diagnoses were as follows: acute myeloid leukemia (2 patients), myelodysplastic syndrome (1 patient), hemophagocytic lymphohistiocytosis (1 patient), T-cell lymphoblastic lymphoma (1 patient), and idiopathic pulmonary hemosiderosis (1 patient). These patients were treated with intrapulmonary rFVIIa concurrent with methylprednisolone, fresh-frozen plasma, and maintenance of the platelet count >50 000/mm3. Complete and sustained hemostasis after rFVIIa treatment and an absence of adverse events were observed in all patients. The PaO2/fraction of inspired oxygen ratio increased significantly, and rapid clinical improvements were observed. Two patients who received hematopoietic stem cell transplantation died of subsequent respiratory syncytial virus and Acinetobacter baumannii infections, but the other 4 patients exhibited rapid improvement, were successfully weaned from ventilators, and experienced long-term survival. Our findings indicate that intrapulmonary administration of rFVIIa is an effective and safe treatment option for children with DAH; however, further clinical studies are needed.
- 1 January 2015
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 135 (1) , e216-e220
Intrapulmonary Recombinant Factor VIIa for Diffuse Alveolar Hemorrhage in Children
Diffuse alveolar hemorrhage (DAH) is a life-threatening pulmonary complication in patients with hematologic malignancies or autoimmune disorders, and it has a high mortality rate. The current treatment options of corticosteroids, transfusions, and immunosuppressants have been limited and largely unsuccessful, and they can be accompanied by multiple complications. Intrapulmonary administration of recombinant activated factor VII (rFVIIa) has been reported in adults, but there are scarce data on its use in children. The present article reviews our institutional experience with intrapulmonary rFVIIa for the treatment of DAH in children. The study included 6 pediatric patients with acute, bronchoscopically confirmed DAH treated between 2011 and 2013. The median age was 11 years, and patient diagnoses were as follows: acute myeloid leukemia (2 patients), myelodysplastic syndrome (1 patient), hemophagocytic lymphohistiocytosis (1 patient), T-cell lymphoblastic lymphoma (1 patient), and idiopathic pulmonary hemosiderosis (1 patient). These patients were treated with intrapulmonary rFVIIa concurrent with methylprednisolone, fresh-frozen plasma, and maintenance of the platelet count >50 000/mm3. Complete and sustained hemostasis after rFVIIa treatment and an absence of adverse events were observed in all patients. The PaO2/fraction of inspired oxygen ratio increased significantly, and rapid clinical improvements were observed. Two patients who received hematopoietic stem cell transplantation died of subsequent respiratory syncytial virus and Acinetobacter baumannii infections, but the other 4 patients exhibited rapid improvement, were successfully weaned from ventilators, and experienced long-term survival. Our findings indicate that intrapulmonary administration of rFVIIa is an effective and safe treatment option for children with DAH; however, further clinical studies are needed.